%0 Journal Article %T Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. %+ Foie, métabolismes et cancer %+ Département d'oncologie médicale [Rennes] %+ Service d'oncologie médicale %+ Microenvironnement et remodelage %+ CRLCC Eugène Marquis (CRLCC) %A Edeline, Julien %A Coulouarn, Cédric %A Crouzet, Laurence %A Pracht, Marc %A Lepareur, Nicolas %A Clément, Bruno %A Garin, Etienne %< avec comité de lecture %@ 1051-0443 %J JVIR: Journal of Vascular and Interventional Radiology %I Elsevier %V 26 %N 12 %P 1874--1878.e2 %8 2015 %D 2015 %R 10.1016/j.jvir.2015.06.032 %M 26596183 %K SIRT %K Yttrium-90 %K chemotherapy %K Hepatocellular carcinoma %K cholangiocarcinoma %Z Life Sciences [q-bio]/Pharmaceutical sciences/Medication %Z Life Sciences [q-bio]/CancerJournal articles %X Synergy between yttrium-90 ((90)Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI \textless 1 denoting synergy and CI \textgreater 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with (90)Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with (90)Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with (90)Y radioembolization for treatment of liver cancer. %G English %2 https://univ-rennes.hal.science/hal-01237102/document %2 https://univ-rennes.hal.science/hal-01237102/file/Gemcitabine%20and%20Oxaliplatin%20but%20Not%20Sorafenib%20or%20Paclitaxel_accepted.pdf %L hal-01237102 %U https://univ-rennes.hal.science/hal-01237102 %~ INSERM %~ UNIV-RENNES1 %~ IFR140 %~ FNCLCC %~ MARQUIS %~ U991 %~ U991-E4 %~ STATS-UR1 %~ NUMECAN %~ NUMECAN-EXPRES %~ NUMECAN-TGTC %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ TEST-UNIV-RENNES %~ TEST-UR-CSS %~ UNIV-RENNES %~ NUMECAN-METHER %~ UR1-BIO-SA %~ TEST3-HALCNRS